Group 1 - The core business of the company is health IoT and digital health services, with main products including smart electronic blood pressure monitors, electronic health scales, smart blood glucose monitoring products, fat measuring devices, ECG monitoring equipment, smart bands, and smartwatches [2] - The company has achieved ISO certifications for medical device quality management and has received international certifications such as FDA registration, EU CE certification, and GMP certification from South Korea, indicating its products meet advanced international quality standards [2] - In the latest quarterly report for Q1 2025, the company reported revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, a year-on-year increase of 67.88%, with a gross profit margin of 37.38% [2] Group 2 - As of May 9, the company's stock closed at 14.46 yuan, down 2.10%, with a rolling PE ratio of 44.51 times and a total market capitalization of 3.145 billion yuan [1] - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing the company at the 86th position in the industry ranking [1][3] - On May 9, the company experienced a net outflow of 9.9992 million yuan in main funds, with a total outflow of 32.6116 million yuan over the past five days [1]
乐心医疗收盘下跌2.10%,滚动市盈率44.51倍,总市值31.45亿元